Gene shot targets diabetic foot pain in early trial
NCT ID NCT01002235
First seen Nov 01, 2025 · Last updated May 17, 2026 · Updated 24 times
Summary
This early-phase study tested the safety of an experimental gene therapy called Engensis (VM202) in 12 adults with painful diabetic nerve damage in their legs. Participants received injections into their leg muscles at different doses. The main goal was to see if the treatment was safe and tolerable, while also checking if it could reduce pain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAINFUL DIABETIC PERIPHERAL NEUROPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Diablo Clinical Research Hospital
Walnut Creek, California, 94598, United States
-
Northwestern Memorial Hospital
Chicago, Illinois, 60611, United States
Conditions
Explore the condition pages connected to this study.